A translational study on mechanism of resistance to PARP inhibitor in patients with breast cancer and gBRCA1/2 mutation (WJOG15321B)
Not Applicable
- Conditions
- germline BRCA1/2 mutation-positive metastatic breast cancer
- Registration Number
- JPRN-UMIN000046007
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Any subject deemed unsuitable by the principal investigator or sub-investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of BRCA1/2 reversion mutation in tumors with acquired resistance to olaparib
- Secondary Outcome Measures
Name Time Method -Frequency of acquired resistance to olaparib by mechanisms other than reversion mutations, including 53BP1 loss, PTIP loss, SLFN11 loss, and PARG loss -Function of BRCA1/2 in cases of putative BRCA1/2 reversion mutations -Differences in the frequency of reversion mutations in BRCA1/2 by number of previous chemotherapy to olaparib